PKC2 is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: Validation of PKC2 as a therapeutic target in chronic lymphocytic leukemia

Blood

Volumn 113, Issue 12, 2009, Pages 2791-2794

  Holler, Claudia ^a   Piñón, Josefina D ^a   Denk, Ursula ^a   Heyder, Christoph ^a   Hofbauer, Sebastian ^a   Greil, Richard ^a   Egle, Alexander ^a  

^a University Hospital Salzburg   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CD5 ANTIGEN; ENZASTAURIN; PROTEIN KINASE C BETA; 2 MORPHOLINO 8 PHENYLCHROMONE; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; CD5 PROTEIN, MOUSE; CHROMONE DERIVATIVE; INDOLE DERIVATIVE; MORPHOLINE DERIVATIVE; ONCOPROTEIN; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; TCL1A PROTEIN, HUMAN; TUMOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CELL POPULATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CLONING; CONTROLLED STUDY; DISEASE COURSE; DRUG TARGETING; GENE; GENE DELETION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TCL1 GENE; VALIDATION PROCESS; AGED; ALLELE; ANIMAL; CROSS BREEDING; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; FEMALE; GENETICS; MALE; MIDDLE AGED; MOUSE MUTANT; PHYSIOLOGY; TRANSGENIC MOUSE; TUMOR CELL LINE;

AGED; AGED, 80 AND OVER; ALLELES; ANIMALS; ANTIGENS, CD5; B-LYMPHOCYTES; CELL LINE, TUMOR; CHROMONES; CROSSES, GENETIC; FEMALE; HUMANS; INDOLES; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MIDDLE AGED; MORPHOLINES; NEOPLASM PROTEINS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 63849093256     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-06-160713     Document Type: Article

References (17)

1. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352:804-815.
2. Tobin G, Thunberg U, Karlsson K, et al. Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia. Blood. 2004;104:2879-2885.
3. Abrams ST, Lakum T, Lin K, et al. B-cell receptor signaling in chronic lymphocytic leukemia cells is regulated by overexpressed active protein kinase CbetaII. Blood. 2007;109:1193-1201.
4. Barragan M, de Frias M, Iglesias-Serret D, et al. Regulation of Akt/PKB by phosphatidylinositol 3-kinase-dependent and -independent pathways in B-cell chronic lymphocytic leukemia cells: role of protein kinase Cb. J Leukoc Biol. 2006;80: 1473-1479.
5. Nakagawa R, Soh JW, Michie AM. Subversion of protein kinase C alpha signaling in hematopoietic progenitor cells results in the generation of a B-cell chronic lymphocytic leukemia-like population in vivo. Cancer Res. 2006;66:527-534.
6. Perez-Chacon G, Vargas JA, Jorda J, et al. CD5 provides viability signals to B cells from a subset of B-CLL patients by a mechanism that involves PKC. Leuk Res. 2007;31:183-193.
7. Ringshausen I, Oelsner M, Weick K, Bogner C, Peschel C, Decker T. Mechanisms of apoptosis-induction by rottlerin: therapeutic implications for B-CLL. Leukemia. 2006;20:514-520.
8. Griner EM, Kazanietz MG. Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer. 2007;7:281-294.
9. Leitges M, Schmedt C, Guinamard R, et al. Immunodeficiency in protein kinase c beta-deficient mice. Science. 1996;273:788-791.
10. Rodriguez A, Villuendas R, Yanez L, et al. Molecular heterogeneity in chronic lymphocytic leukemia is dependent on BCR signaling: clinical correlation. Leukemia. 2007;21:1984-1991.
11. Bichi R, Shinton SA, Martin ES, et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci USA. 2002;99:6955-6960.
12. Yan XJ, Albesiano E, Zanesi N, et al. B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2006;103:11713-11718.
13. Ma S, Rosen ST. Enzastaurin. Curr Opin Oncol. 2007;19:590-595.
14. Tinhofer I, Rubenzer G, Holler C, et al. Expression levels of CD38 in T cells predict course of disease in male patients with B-chronic lymphocytic leukemia. Blood. 2006;108:2950-2956.
15. Merkel O, Heyder C, Asslaber D, et al. Arsenic trioxide induces apoptosis preferentially in B-CLL cells of patients with unfavourable prognostic factors including del17p13. J Mol Med. 2008;86:541-552.
16. Laine J, Kunstle G, Obata T, Sha M, Noguchi M. The protooncogene TCL1 is an Akt kinase coactivator. Mol Cell. 2000;6:395-407.
17. Graff JR, McNulty AM, Hanna KR, et al. The protein kinase Cb-selective Inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res. 2005;65:7462-7469.